Table 2.

Comparison of Frequency of Second Cancers in CLL Patients after Frontline FCR based therapies with SEER Data

Variable*	Observed	Expected	O/E	95% CI for O/E
Overall	26	10.92	2.38	1.55 – 3.50
Male	20	9.03	2.21	1.35 – 3.41
Female	6	1.9	3.16	1.15 – 6.88
Age ≥ 60 y	19	7.3	2.60	1.56 – 4.06
Age < 60 y	7	3.6	1.94	0.78 – 4.00
Second cancer type
t-AML/MDS	12	0.05	240	124.08 - 420
Lung	3	2.57	1.17	0.24 – 3.40
Colon	2	1.38	1.45	0.17 – 5.23
Prostate	2	2.85	0.70	0.08 – 2.53

^*Excluded Richter’s Transformation, non-melanoma skin cancers and cancer within 12 months of therapy.

Abbreviations: y,years; t-AML/MDS, therapy related acute myeloid leukemia or myelodysplastic syndrome